Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCG142 in advanced HPV-positive carcinomas
NCT06505551Phase 2Not yet recruiting
- Sponsor
- SCG Cell Therapy
- Start
- Oct 2024
- Primary completion
- Dec 2026
- Modality
- TCR-Engineered T Cells
01
Overview
Phase 2, open-label, single-arm trial of SCG142 in squamous cell carcinoma (SCC), sponsored by SCG Cell Therapy. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 2 years and Objective Response Rate at 2 years. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
SCG142
03
Conditions
squamous cell carcinoma (SCC)
Beyond the preview
Go deeper on NCT06505551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06505551.